In December 2023, part of the UroTarget team carried out the highest GU tumor board in the world in Cordón del Plata, Mendoza (4300mts-14100ft). Daniel Castellano FLoscoMD Martín Angel Dr. Tomás Soulé Martin Richardet Gustavo Losco #mountains #mountainlife

#GUcancer Must read lecture! EV302 trial! 🦾🦾🦾nejm.org/doi/full/10.10… OncoAlert UroTarget UroToday.com blatam uro Eur Urol Focus Uromigos

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

Taller de teragnostico en cáncer de prostata con Martín Angel en Post GU-GI #Bariloche UroTarget UroTeragLATAM Urooncologia.arg Asociación Argentina de Oncología Clínica (AAOC)

UroTarget 2024! 31 de Octubre-1,2 de Noviembre 2024 Powered by Asociación Argentina de Oncología Clínica (AAOC) Urooncologia.arg

Terrific paper from Neeraj Agarwal, MD, FASCO Daniel Castellano et al in Clinical Cancer Research re: #abemaciclib in #metastatic #prostatecancer ... full article here: aacrjournals.org/clincancerres/…

🎯 Starting the Advanced Prostate Cancer Consensus Conference meeting with excellent Translational Prostate Cancer Symposium!! 😎 OncoAlert Yüksel Ürün 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Prostate Cancer Foundation silke gillessen

What's the role of DRE in PC diagnosis? Excellent presentation by Declan Murphy in Advanced Prostate Cancer Consensus Conference

Amazing presentation by Piet Ost about the role of RT in localized HRPC Advanced Prostate Cancer Consensus Conference The #teamwork is the key

persistencia de PSA 0,7ng y/o ALTO RIESGO con dos factores hay que tratar al pte, con PSA 0,2NG sin factores de riesgo se discute . #SIHAYCONSENSO 🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! Juan Pablo Sade Urooncologia.arg EAU Edu Platform UROONCO UroTarget

The challenge of management of patients with mHSPC and early progression on combination therapy by Christopher Sweeney, MBBS Advanced Prostate Cancer Consensus Conference #APCCC24

What can we do in mCRPC after triplet therapy. Excellent presentation by Dr Karim Fizazi (Gustave Roussy) and unplublished data from PEACE-1

"Side effects usually occur earlier with iPARP treatment" Elena Castro Advanced Prostate Cancer Consensus Conference

NEPC (Neuroendocrine PC) vs AVPC (Agressive Variants of PC) by Andrew Armstrong in Advanced Prostate Cancer Consensus Conference 2024 OncoAlert UroToday.com CLOC: Curso Latinoamericano de Oncología Clínica Urooncologia.arg

Excellent presentation by Michael Hofman about PSMA ligands Advanced Prostate Cancer Consensus Conference UroTeragLATAM PSMA and Beyond Conference Urooncologia.arg

⁦⁦UroTarget⁩ multidisciplina en #urooncologia. Ciencia y amigos. ⁩ urotoday.com/video-lectures… ⁦OncoAlert⁩ ⁦Oficina Residentes CAU⁩ ⁦RAEU - Spanish Urology Residents Working Group⁩ ⁦UroToday.com⁩ ⁦Confederación Americana de Urología (CAU)⁩

UroTarget plus Uromigos. Enjoying the night with the best Tom Powles Neeraj Agarwal, MD, FASCO Martín Angel #ASCO24

PRO data from EV302 (EVP vs chemo) in 1st line UC assesses pain/global heath scores,many of which are similar in the 2 groups. Exploratory differences favouring EVP identified,particularly in those with symptoms.Novel method were used but accurate PRO assessment imperfect #ASCO24

🆂🅰🆅🅴 🆃🅷🅴 🅳🅰🆃🅴 3er curso teragnóstico en Cáncer de Próstata by UroTeragLATAM

🚨 Exciting Update! 🚨 Our new EVITA (EV Ineligible criTeriA) criteria for identifying patients ineligible for the EV/Pembro combo in #metastaticurothelialcarcinoma has just been published in European Urology!!!! This breakthrough could significantly reshape daily clinical practice!